Sabicard 24 mg+26 mg (Tablet)
Unit Price: ৳ 45.00 (1 x 10: ৳ 450.00)
Strip Price: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Aristopharma ltd |
| Also available as |
Indications
- Reduces risk of cardiovascular death
- Hospitalization for heart failure
- Chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction
- Treatment of symptomatic heart failure
- Systemic left ventricular systolic dysfunction
- Pediatric patients aged one year and older
- Administered in conjunction with other heart failure therapies
Pharmacology
- Contains neprilysin inhibitor (sacubitril) and angiotensin receptor blocker (valsartan)
- Inhibits neprilysin (neutral endopeptidase) via LBQ657
- Blocks the angiotensin II type-1 (AT1 ) receptor via valsartan
- Increases levels of peptides degraded by neprilysin
- Simultaneously inhibits the effects of angiotensin II by valsartan
- Inhibits angiotensin II-dependent aldosterone release
Dosage & Administration
- Recommended starting dose for adult heart failure is 49/51 mg orally twice daily
- Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily
- Reduce the starting dose to 24/26 mg twice daily for specific patient groups
- Pediatric patients aged one year and older have a recommended dose adjustment
Interaction
- Avoid dual blockade of the Renin-Angiotensin-Aldosterone System
- Avoid concomitant use of ACE inhibitors and aliskiren in patients with diabetes
- Use with ARB should be avoided
- Potassium-sparing diuretics may increase serum potassium level
- NSAIDs may increase risk of renal impairment
- Lithium may increase risk of lithium toxicity
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors or aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required for patients with mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
Precautions & Warnings
- May cause angioedema
- Must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy
- Lowers blood pressure and may cause symptomatic hypotension
- Monitor serum creatinine and renal function
- Monitor serum potassium periodically and treat appropriately
- Dosage reduction or interruption may be required
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences observed in elderly patients
- Dose adjustment for severe renal impairment
- Dose adjustment for moderate hepatic impairment
- Not recommended in patients with severe hepatic impairment
Overdose Effects
- Limited data available for overdosage
- Hypotension likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis due to high protein binding
Storage Conditions
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children